Cistadenoma mucinoso retroperitoneal primário - relato de caso

Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM)UNIFESP, EPMSciEL

Análise da correlação entre a expressão da p53 e do bcl-2 com o estadiamento e o prognóstico do adenocarcinoma colorretal

PURPOSE: To analyze the correlation between p53 and bcl-2 expression and colorectal adenocarcinoma staging and prognosis. METHODS: This was a retrospective series of 125 colorectal adenocarcinoma patients (67 women and 58 men; ages 30-87 years) who underwent surgery with curative intent. The mean follow-up was 28.5 months (range: 2-96 months). TNM staging, tumor recurrence, survival and cancer-related mortality were analyzed. Immunoreactivity was evaluated using DO7 (Dako) for p53 and K492 (Dako) for bcl-2. Tumors with accumulation of staining for cytoplasmic bcl-2 or nuclear p53 in more than 10% of cells were considered positive. Statistical analysis utilized Pearson chi-squared, log-rank and Wilcoxon tests, and Kaplan-Meier survival estimation (significance level: p<0.05). RESULTS: p53+ was found in 11.8% (14/118), bcl-2+ in 50% (58/116) and associated p53+/bcl-2+ in 6.4% (7/109) of the tumors. There was no significant correlation between expression of these biomarkers and TNM I, II, III and IV staging (p=0.385 for p53; p=0.461 for bcl-2). For tumor recurrence, p53+ was found in 9.5% (2/21), bcl-2+ in 50% (11/22), and associated p53+/bcl-2+ in 5.2% (1/19) of the tumors (p=0.714, p=1.000 and p=0.960, respectively). For survival analysis, p53+: 57 months (45.0-68.0), bcl-2+: 78 (37.0-89.0), and p53+/bcl-2+: 62 (56.0-68.0) (p=0.319). For cancer-related mortality, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), and p53+/bcl-2+: 5.9% (2/36) of the patients (p=0.432, p=0.688 and p=0.907, respectively). CONCLUSION: No correlation was found between tumor expression of p53 and bcl-2 and the TNM staging, recurrence, survival and cancer-related mortality in colorectal adenocarcinoma.OBJETIVO: Analisar a correlação entre a expressão da p53 e do bcl-2 com o estadiamento e prognóstico do adenocarcinoma colorretal. MÉTODOS: Foi realizado o estudo de uma série retrospectiva de 125 doentes com adenocarcinoma colorretal (67 mulheres e 58 homens; 30 a 87 anos de idade), que se submeteram ao tratamento cirúrgico com intenção curativa. O tempo médio de seguimento foi de 28,5 meses (variação de 2 a 96 meses). O estadiamento TNM, a recidiva tumoral, a sobrevida e a mortalidade relacionada com o câncer foram analisados. A reação imunohistoquímica utilizada foi o DO& (Dako) para o p53 e o K492 (Dako) para o bcl-2. Tumores com intensidade de coloração citoplásmica para o bcl-2 e nuclear para o p53, acima de 10% de células foram considerados positivos. A análise estatística utilizada foi o teste qui-quadrado de Pearson, log-rank, Wilcoxon e estimativa de sobrevida de Kaplan-Meier (nível de significância : p<0,05). RESULTADOS: p53+ foi encontrado em 11.8% (14/118), bcl-2+ em 50% (58/116) e associados p53+/bcl-2+ em 6.4% (7/109) dos tumores. Não foi encontrado correlação significante entre a expressão tumoral destes marcadores e o estadiamento TNM I, II, III e IV (p=0.385 para a p53; p=0.461 para o bcl-2). Na recidiva tumoral, p53+ foi encontrado em 9.5% (2/21), bcl-2+ em 50% (11/22), e p53+/bcl-2+ associados em 5.2% (1/19) dos tumores (p=0.714, p=1.000 e p=0.960, respectivamente). Na análise de sobrevida, p53+: 57 meses (45.0-68.0), bcl-2+: 78 (37.0-89.0), e p53+/bcl-2+: 62 (56.0-68.0) (p=0.319). Para mortalidade relacionada com câncer, p53+: 8.3% (3/36), bcl-2+: 47.2% (17/36), e p53+/bcl-2+: 5.9% (2/36) dos pacientes (p=0.432, p=0.688 and p=0.907, respectivamente). CONCLUSÃO: Nenhuma correlação significante foi encontrada entre a expressão tumoral da p53 e do bcl-2 com o estadiamento TNM, recidiva, sobrevida e mortalidade relacionada com câncer.Centro Universitário de Volta RedondaUNIFESP-EPM Pathology DepartmentUNIFESP-EPM Surgical Gastroenterology DepartmentUNIFESP, EPM, Pathology DepartmentUNIFESP, EPM Surgical Gastroenterology DepartmentSciEL

Neonatal necrotizing enterocolitis rat model attenuated by a remote ischemic preconditioning in the pregnant

Purpose: To evaluate the effect of remote ischemic preconditioning (r-IPC) administered to pregnant rats, in the ileum of newborn rats subjected to hypoxia and reoxygenation. Methods: We used three pregnant rats and their newborn rats distributed in three groups: 1) Control (C) - Newborn rats born from a pregnant rat which did not undergo any intervention2) Hypoxia-Reoxygenation (H/R) - Newborn rats born from a pregnant rat which did not undergo any intervention, and were subjected to hypoxia-reoxygenation3) Remote Ischemic Preconditioning (r-IPC) - newborn rats born from a pregnant rat which was subjected to remote ischemic preconditioning twenty-four hours before giving birth and the newborn rats were subjected to hypoxia-reoxygenation. Segments of ileum were prepared for histological analysis by HE and immunohistochemistry by the Ki67 to evaluate cell proliferation, crypt depth and villus height and evaluation of apoptosis by cleaved caspase-3. Results: The intensity of the lesions was lower in the r-IPC than in the H/R group, showing significant difference (p H/R - p H/R - (p < 0.01). The occurrence of apoptosis in the H/R group was lower in comparison to groups C and r-IPC, with significant difference (H/R < r-IPCp<0.05). Conclusion: The remote ischemic preconditioning applied to the pregnant rat protected the ileum of newborn rats subjected to hypoxia and reoxygenation, with decreased intensity of the lesions in the ileum mucosa and preservation of proliferative activity, keeping the villus height and crypt depth similar to group C.Univ Fed Sao Paulo UNIFESP, Postgrad Program Interdisciplinary Surg Sci, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, SP, BrazilUniv Sao Paulo, Sch Med, Dept Surg, Lab Surg Physiopathol LIM 62, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Surg, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Pediat Surg, Sao Paulo, SP, BrazilUniv Fed Sao Paulo UNIFESP, Pediat Surg Res Lab, Sao Paulo, BrazilUniv Fed Sao Paulo UNIFESP, Postgrad Program Interdisciplinary Surg Sci, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Pathol, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Surg, Sao Paulo, SP, BrazilUniv Fed Sao Paulo, Dept Pediat Surg, Sao Paulo, SP, BrazilUniv Fed Sao Paulo UNIFESP, Pediat Surg Res Lab, Sao Paulo, BrazilWeb of Scienc